

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (Currently amended) A method of expanding a population of stem or progenitor cells, the method comprising steps of:
providing at least one stem or progenitor cell with less than wild type p21 activity; and
expanding the cell population.
2. (Currently amended) The method of claim 1, wherein the step of providing comprises:
providing a stem or progenitor cell; and
disrupting the cell's p21 gene.
3. (Currently amended) The method of claim 1, wherein the step of providing comprises:
providing a stem or progenitor cell; and
contacting the cell with an agent, wherein the agent inhibits p21 activity.
4. (Original) A method of expanding a population of cells, the method comprising the steps of:
providing at least one cell with less than wild type p27 activity and less than wild type p21 activity; and
expanding the cell population.
5. (Original) The method of claim 4, wherein the step of providing comprises:
providing a cell; and
disrupting p27 and p21 genes.
6. (Original) The method of claim 4, wherein the step of providing comprises:

providing a cell; and
contacting the cell with an agent, wherein the agent inhibits p27 and p21 activity.

7. (Original) The method of claim 1, wherein the cell is a stem cell.
8. (Original) The method of claim 1, wherein the cell is a hematopoietic stem cell.
9. (Original) The method of claim 1, wherein the cell is a hematopoietic progenitor cell.
10. (Original) The method of claim 1, wherein the cell is an erythropoietic cell.
11. (Original) The method of claim 1, wherein the cell is a granulopoietic cell.
12. (Original) The method of claim 1, wherein the cell is a thrombopoietic cell.
13. (Original) The method of claim 1, wherein the cell is a neural cell.
14. (Original) The method of claim 1, wherein the cell is selected from the group consisting of renal cell, gastrointestinal cell, hepatic cell, skin cell, lung cell, muscle cell, and cardiac muscle cell.
15. (Original) The method of claim 1, wherein the cell is an adult-derived stem cell.
16. (Original) The method of claim 1, wherein the cell is an embryonically derived stem cell.
17. (Original) The method of claim 1, wherein the cell is a pluripotent stem cell.
18. (Original) The method of claim 1, wherein the cell is a multi-potential stem cell.

19. (Original) The method of claim 1, wherein the cell is a fetal cell.
20. (Original) The method of claim 1, wherein the cell is an embryonic cell.
21. (Original) The method of claim 1, wherein the cell is a mesenchymal cell.
22. (Original) The method of claim 3, wherein the agent is a protein.
23. (Original) The method of claim 3, wherein the agent is a peptide.
24. (Original) The method of claim 3, wherein the agent is a polynucleotide.
25. (Original) The method of claim 3, wherein the agent is a chemical compound.
26. (Original) The method of claim 3, wherein the agent is an antibody or fragment thereof.
27. (Original) The method of claim 3, wherein the agent is an antisense agent.
28. (Original) The method of claim 3, wherein the agent is a triple helix forming agent.
29. (Original) The method of claim 3, wherein the agent is an aptamer.
30. (Currently amended) A stem or progenitor cell with less than wild type p21 activity.
31. (Currently amended) A stem or progenitor cell with at least one copy of the p21 gene disrupted.
32. (Currently amended) A stem or progenitor cell with both copies of the p21 gene disrupted.

33. (Original) A cell with less than wild type p27 activity.
34. (Original) A cell with at least one copy of the p27 gene disrupted.
35. (Original) A cell with at least one copy of the p27 gene and p21 gene disrupted.
36. (Original) The cell of claim 30, wherein the cell is a stem cell.
37. (Original) The cell of claim 30, wherein the cell is a progenitor cell.
38. (Original) A stem cell with increased cyclin activity.
39. (Original) A progenitor cell with increased cyclin activity.
40. (Original) A stem cell with increased cyclin-dependent kinase activity.
41. (Original) A progenitor cell with increased cyclin-dependent kinase activity.
42. (Original) A pharmaceutical composition comprising a therapeutically effective amount of cells of claim 30.
43. (Original) A pharmaceutical composition comprising a therapeutically effective amount of stem cells of claim 36.
44. (Original) A pharmaceutical composition comprising a therapeutically effective amount of progenitor cells of claim 37.
45. (Original) A pharmaceutical composition comprising a therapeutically effective amount of cells of claim 30, and a pharmaceutically acceptable excipient.

46. (Canceled)
47. (Canceled)
48. (Canceled)
49. (Canceled)
50. (Canceled)
51. (Canceled)
52. (Canceled)
53. (Canceled)
54. (Canceled)
55. (Canceled)
56. (Canceled)
57. (Canceled)
58. (Canceled)
59. (Canceled)
60. (Canceled)

61. (Canceled)
62. (Canceled)
63. (Canceled)
64. (Canceled)
65. (Canceled)
66. (Canceled)
67. (Canceled)
68. (Canceled)
69. (Canceled)
70. (Canceled)
71. (Canceled)
72. (Canceled)
73. (Canceled)
74. (Canceled)
75. (New) The method of claim 3, wherein the agent is an RNA inhibiting agent.